Phosphorylated RKIP as a Predictor of Lung Cancer Survival
Author Information
Author(s): Huerta-Yepez Sara, Yoon Nam K, Hernandez-Cueto Angeles, Mah Vei, Rivera-Pazos Clara M, Chatterjee Devasis, Vega Mario I, Maresh Erin L, Horvath Steve, Chia David, Bonavida Benjamin, Goodglick Lee
Primary Institution: Unidad de Investigacion en Enferemedades Oncologicas, Hospital Infantil de Mexico, Federico Gomez, SSa, Mexico
Hypothesis
Does the expression of phosphorylated RKIP (pRKIP) predict survival outcomes in lung cancer patients?
Conclusion
Phosphorylated RKIP is a significant predictor of survival in lung cancer patients, especially in those with early-stage disease and older age.
Supporting Evidence
- Higher levels of pRKIP were associated with better survival outcomes.
- The study found that pRKIP expression was particularly predictive in patients over 65 years old.
- Patients with early-stage lung cancer showed a stronger correlation between pRKIP levels and survival.
Takeaway
This study found that higher levels of a protein called pRKIP in lung cancer patients can help predict how long they might live after diagnosis.
Methodology
The study used a lung tissue microarray to analyze RKIP and pRKIP expression in lung cancer samples.
Limitations
The study did not explore the mechanistic basis for the observed differences in RKIP and pRKIP expression.
Participant Demographics
{"age":{"median":66,"range":"26 - 86"},"sex":{"male":175,"female":197},"smoking_history":{"current_smoker":53,"previously_smoked":257,"second_hand_smoke":11,"non_smoker":39,"unknown":12},"histology":{"adenocarcinoma":222,"squamous_cell_carcinoma":106,"adenosquamous_carcinoma":20,"bronchioloalveolar_carcinoma":24},"clinical_stage":{"I":209,"II":68,"III":69,"IV":24,"unknown":2}}
Statistical Information
P-Value
0.0118
Confidence Interval
1.10 - 2.15
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website